The 12-month’s insider sell/buy ratio of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) is recorded at 4, pointing to bearish feelings about the stock among corporate executives and directors. SGYP corporate insiders offloaded 425,556 shares in the past 12 months while buyers snapped up no shares in the same period.
Paulson & Co. Inc. parted with a total of 8.75 million shares of Synergy Pharmaceuticals Inc. (SGYP) at average share price of $2.82. This insider trade in the company took place on 11/10/2017. The total for the sales was set at $24.68 million. After this transaction, the 10% Owner account balance stood at 15.31 million shares. The stock lost -92.91 percent since that insider sale. On 08/07/2017, Paulson & Co. Inc., 10% Owner, sold 26.29 thousand shares at a price per share of $3.77. This removed 99.1 thousand shares from the insider’s fortune and the stock saw a -94.69 percent retreat in value since the news became public. This transaction left 24.06 million shares in the 10% Owner account.
On 05/26/2017, CEO Jacob Gary S performed a purchase transaction worth $19.99 thousand. This purchase at $3.52 each has added 5.68 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -94.32 percent decrease since the transaction was reported. The insider now is left with 402.68 thousand shares remaining in the account. Brancaccio John P, who performs the Director job, bought 6.5 thousand shares for $23.34 thousand. The acquisition occurred on 05/26/2017 was priced at $3.59 per share. The share price plunged -94.43 percent since the reporting date. Brancaccio John P now left with a stake of 30.44 thousand SGYP stock worth $6.09 thousand after the insider buying.
The 12-month median price target for Synergy Pharmaceuticals Inc. (SGYP) assigned by the analysts stands at $2, which represents a return potential of 900 percent when compared to the closing price of the stock of $0.2 on Friday, January 11. The lowest price target for the stock is $2 — slightly more than 900 percent from SGYP’s current share price. The stock will probably climb 900 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $2-month high price target. This represents a whopping 900 percent increase from where shares are trading today.
On momentum oscillators front, ‘RSI’ has touched 46.96 on daily chart, which may remain a cause for concern. If the price breaks below $0.17 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.22 mark may result into a pull-back move towards $0.24 level. The stock is currently hovering around the first support level of $0.18. Below this, the next support is placed in the zone of $0.17. Till the time, the SGYP stock trades above this level, bulls have nothing to fear.
Shares of Synergy Pharmaceuticals Inc. (SGYP) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry SGYP operates in has an average P/E of 69.71. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 1.38 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 67.4 percent is the gross profit margin for Synergy Pharmaceuticals Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
On 11th of January, Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares ended lower after a volatile session. The shares dropped -0.03 points or -14.48 percent at $0.2 with a light trade volume of 8.032 million shares. After opening the session at $0.23, the shares went as high as $0.23 and as low as $0.195, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $56.91 million and now has 289.34 million shares outstanding. Synergy Pharmaceuticals Inc. (SGYP) stock has lost -41.98 percent of market value in 21 trading days.
SGYP stock has a trailing 3-year beta of 3.59, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.56 a share in the trailing twelve months. The stock’s value has surged 72.7 percent year to date (YTD) against a decline of -91.45 percent in 12 month’s time. The company’s shares still trade -92.97 percent away from its 1-year high of $2.80 and 181 percent up from 52-week low of $0.07. The average consensus rating on the company is 2.7, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.